Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Antiviral drug stops COVID-19 transmission in ferrets 

By Brian Buntz | December 30, 2020

Ferret

Image from Wikipedia

Molnupiravir, an experimental antiviral drug developed by Emory University, Merck (NYSE:MRK) and Ridgeback Biotherapeutics, has promise in the battle against COVID-19 based on an animal trial published in Nature from Georgia State University researchers.  

Also known as MK-4482 or EIDD-2801, the oral drug Molnupiravir has an advantage over SARS-CoV-2 therapies such as remdesivir and reconvalescent serum that require infusion. Molnupiravir blocked SARS-CoV-2 infection and transmission in ferrets, which generally transmit the virus similar to young human adults. 

In the study, the drug was administered to the animals twice daily, curbing viral load in the ferrets and entirely blocking spread to untreated contact animals. If the drug performs similarly in humans, it could be a useful tool in curbing community transmission of COVID-19.  

Emory University researchers initially developed MK-4482 as an anti-influenza agent. A prodrug of the nucleoside analog N4-hydroxycytidine (NHC), MK-4482, proved to be effective at curbing flu infections in mice, guinea pigs, ferrets and human-airway organoids. NHC also proved to have a broad-spectrum effect against RNA viruses. 

One reason the researchers chose minks for their investigation is that mouse models of SARS-CoV-2 are limited. The novel coronavirus cannot transmit to mice without adapting the virus or using transgenic rodents. Human SARS-CoV-2, however, has infected farmed minks and resulted in substantial transmission between animals and, occasionally, back to humans.  

At least nine countries have had COVID-19 outbreaks in mink farms, according to the Atlantic. Minks are closely related to ferrets.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: anti-influenza, coronavirus, covid-19, ferrets, influenza, Merck, minks, Ridgeback Biotherapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50